Y Streamline - Retrospective Cohort Study of Relapsed or Refractory (R/R) FLT3-Mutated Acute Myeloid Leukemia (AML): Real-World Treatment, Testing Patterns, and Outcomes

被引：0
|
作者：
Zeidan, Amer M.
Gilligan, Adrienne M.
Gautam, Santosh
Grinblatt, David L.
Elsouda, Dina
Sullivan, Loretta
Pandya, Bhavik J.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-136366
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Streamline - Retrospective Cohort Study of FLT3-mutated Acute Myeloid Leukemia (AML): Real-World Treatment Patterns and Clinical Outcomes after First Relapse or Refractory (R/R) Diagnosis
    Zeidan, Amer M.
    Gautam, Santosh
    Yu, Rebekah
    Lan, Ziyu
    Grinblatt, David L.
    ElSouda, Dina
    Spalding, James
    Block, Alana
    Touya, Maelys
    Pandya, Bhavik J.
    [J]. BLOOD, 2022, 140 : 8124 - 8126
  • [2] Gilteritinib and Venetoclax for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia - a Real-World Multicenter Retrospective Study
    Kugler, Eitan
    Cohen, Inbar
    Ram, Ron
    Canaani, Jonathan
    Amitai, Irina
    Shargian, Liat
    Nachmias, Boaz
    Krayem, Baher
    Frisch, Avraham
    Levi, Itay
    Akria, Luiza
    Raanani, Pia
    Wolach, Ofir
    Kugler, Eitan
    [J]. BLOOD, 2023, 142
  • [3] Streamline - Study of Relapse or Refractory (R/R) FLT3-Mutated Acute Myeloid Leukemia (AML) Using Electronic Medical Records (EMR): First Analysis from a Multicenter, Retrospective Cohort Study
    Zeidan, Amer M.
    Gilligan, Adrienne
    Gautam, Santosh
    Hu, Nan
    Grinblatt, David L.
    Pandya, Bhavik J.
    [J]. BLOOD, 2019, 134
  • [4] Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia
    McMahon, Christine M.
    Perl, Alexander E.
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (09) : 841 - 849
  • [5] GILTERITINIB IN RELAPSED/REFRACTORY FLT3-MUTATED AML: AN ITALIAN MULTICENTER REAL-WORLD EXPERIENCE
    Brunetti, L.
    Sciabolacci, S.
    Cardinali, V.
    Capelli, D.
    Menotti, D.
    Parisi, M. S.
    Maugeri, C.
    Mauro, E.
    Condorelli, A.
    Rondoni, M.
    Grimaldi, F.
    Olivieri, A.
    Vetro, C.
    Saraceni, F.
    Martelli, M. P.
    [J]. HAEMATOLOGICA, 2022, 107 : 71 - 72
  • [6] Emerging Real-World Midostaurin Treatment Patterns and Outcomes in FLT3-Mutated Acute Myeloid Leukemia at a Comprehensive Cancer Center
    Willis, Connor
    Menon, Jyothi
    Unni, Sudhir
    Au, Trang
    Ndife, Briana
    Joseph, George J.
    Bonifacio, Gaetano J.
    Stein, Eytan M.
    Tantravahi, Srinivas K.
    Shami, Paul J.
    Kovacsovics, Tibor
    Brixner, Diana
    Stenehjem, David Dean
    [J]. BLOOD, 2018, 132
  • [7] Real-World Use of FLT3-TKIs in R/R FLT3-Mutated AML in the United States
    Grinblatt, David L.
    Pandya, Bhavik J.
    Han, Wei
    Sullivan, Loretta
    Feng, Qi
    Hedlund, Nancy
    [J]. BLOOD, 2020, 136
  • [8] Iadademstat and Gilteritinib for the Treatment of FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia: The Frida Study
    Fathi, Amir T.
    Braun, Theodore P.
    Ambinder, Alexander Joseph
    Borthakur, Gautam
    Redner, Robert L.
    Arevalo, Mabel
    Gutierrez, Sonia
    Limon, Ana
    Faller, Douglas V.
    [J]. BLOOD, 2023, 142
  • [9] Post-transplant maintenance therapy in patients with FLT3-mutated acute myeloid leukemia: Real-world treatment patterns and outcomes
    Griffin, James D.
    Song, Yan
    Yang, Hongbo
    Freimark, Jonathan
    Shah, Manasee, V
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 107 (05) : 553 - 565
  • [10] PATIENT-REPORTED OUTCOMES AND THEIR RELATIONSHIP WITH CLINICAL OUTCOMES IN PATIENTS WITH FLT3-MUTATED (FLT3MUT+) RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PHASE 3 ADMIRAL STUDY
    Cella, D.
    Ritchie, E.
    Fabbiano, F.
    Pigneux, A.
    Kanda, Y.
    Ivanescu, C.
    Pandya, B.
    Shah, M., V
    [J]. VALUE IN HEALTH, 2019, 22 : S531 - S531
12345